Literature DB >> 19856060

Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

Tadaaki Yamada1, Koushiro Ohtsubo, Hisatsugu Mouri, Kaname Yamashita, Kazuo Yasumoto, Kouji Izumi, Yoh Zen, Hiroyuki Watanabe, Seiji Yano.   

Abstract

We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis. In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered. Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed efficacy in targeting the small cell carcinoma. In March 2008, he presented with signs of meningeal irritation; his condition deteriorated quickly and multiple brain metastases were confirmed by magnetic resonance imaging (MRI). A sample of cerebrospinal fluid collected by lumbar puncture showed cancer cells and an elevated level of ProGRP. Small cell carcinoma of the prostate complicated with meningeal carcinomatosis was diagnosed. A different chemotherapy regimen was then administered, consisting of a combination of carboplatin plus irinotecan, which is one of the most common first-line treatments for extensive-stage small cell lung carcinoma. From day 20 after the initiation of this therapy, he gradually recovered from the signs of meningeal irritation, and brain MRI showed nearly normal findings; also, the serum level of ProGRP was reduced. In conclusion, we report the efficacy of combined treatment with carboplatin plus irinotecan for small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Because this clinical condition is extremely rare, a gold standard treatment has yet to be established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856060     DOI: 10.1007/s10147-008-0869-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  23 in total

1.  Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer.

Authors:  Wendy B Bernstein; Jean D Kemp; Geoffrey S Kim; Viviana V Johnson
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

2.  Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma.

Authors:  M P Castro; T J McDonald; S J Qualman; T M Odorisio
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

3.  Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.

Authors:  Hiroshi Aoki; Shigeto Ishidoya; Akihiro Ito; Mareyuki Endoh; Toru Shimazui; Yoichi Arai
Journal:  Int J Urol       Date:  2006-09       Impact factor: 3.369

4.  Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.

Authors:  Nobuyuki Naka; Masaaki Kawahara; Kyoichi Okishio; Shigeto Hosoe; Mitsumasa Ogawara; Shinji Atagi; Yuuji Takemoto; Kiyonobu Ueno; Tomoya Kawaguchi; Tessei Tsuchiyama; Kiyoyuki Furuse
Journal:  Lung Cancer       Date:  2002-09       Impact factor: 5.705

Review 5.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

6.  Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

Authors:  Takashi Hirose; Naoya Horichi; Tohru Ohmori; Keiichi Ogura; Takamichi Hosaka; Kohichi Ando; Hiroo Ishida; Hisashi Noguchi; Mitsuru Adachi
Journal:  Lung Cancer       Date:  2003-06       Impact factor: 5.705

7.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Authors:  Christos N Papandreou; Danai D Daliani; Peter F Thall; Shi-Ming Tu; Xuemei Wang; Adriana Reyes; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

Review 8.  Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy.

Authors:  S R Moore; Y Reinberg; G Zhang
Journal:  Urology       Date:  1992-05       Impact factor: 2.649

9.  Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.

Authors:  J E Oesterling; C G Hauzeur; G M Farrow
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.

Authors:  H Okamoto; K Watanabe; H Kunikane; A Yokoyama; S Kudoh; T Asakawa; T Shibata; H Kunitoh; T Tamura; N Saijo
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

View more
  1 in total

Review 1.  Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment.

Authors:  Tomoyuki Makino; Kouji Izumi; Atsushi Mizokami
Journal:  Biomedicines       Date:  2021-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.